GOVX Profile
GeoVax Labs, Inc., a clinical-stage biotechnology company, specializes in developing human vaccines and immunotherapies targeting infectious diseases and cancers. Utilizing its proprietary modified vaccinia Ankara virus-like particle (MVA-VLP) vaccine platform, GeoVax is at the forefront of creating innovative solutions for global health challenges. The company's platform leverages the safety and efficacy of the MVA vector to produce robust immune responses, making it a promising candidate for a variety of critical applications.
The company's extensive pipeline includes preventive vaccines for COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and several hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is advancing therapeutic vaccines aimed at treating chronic conditions, including HIV, chronic hepatitis B infections, and solid tumor cancers. These developments underscore the company's commitment to addressing both emerging and persistent public health threats.
GeoVax Labs maintains a robust network of collaborations and partnerships with leading institutions and agencies. These include the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. These partnerships enhance the company's research capabilities and facilitate the advancement of its vaccine candidates through various stages of development and clinical trials.
Incorporated in 1988 and headquartered in Smyrna, Georgia, GeoVax Labs, Inc. combines decades of expertise with cutting-edge technology to develop groundbreaking vaccines and immunotherapies. By focusing on high-impact infectious diseases and cancers, the company aims to improve global health outcomes and contribute significantly to the field of biotechnology.
|
